More EVs. Less effort. Lower cost.
The EVlution™ TFF System delivers high-yield, high-purity EV purification from up to 3 litres of starting material - in just 90 minutes. Unlike ultracentrifugation, EVlution™ is affordable, easy to use, and requires minimal hands-on time, freeing you to focus on what matters most: your research.
Its innovative Switch Flow™ technology reduces retentate volume to under 10 mL, maximising recovery while minimising loss. The compact, modular design supports 12 interchangeable polyethersulfone hollow fibre cartridge sizes, including the widely used 300 kDa and 500 kDa options optimised for EV concentration. Filters are reusable up to 20 times, keeping running costs low. EVlution™ pairs seamlessly with Exo-spin™ purification columns for a complete, end-to-end EV workflow.
Whether you're concentrating EVs, depleting FBS-associated particles, or performing buffer exchange, EVlution™ has you covered.
Not all extracellular vesicles are the same. Learn how exosomes, microvesicles and apoptotic bodies differ in size, biogenesis and cargo, and why the distinction matters for reproducible EV research.
MSC-derived exosomes (and other extracellular vesicles) have become one of the most actively investigated modalities in regenerative medicine, with peer-reviewed evidence spanning cardiac repair, neural regeneration, wound healing, bone and cartilage restoration, and acute organ injury. This article reviews the biological basis of MSC exosome activity, the therapeutic evidence across key disease areas, the manufacturing and isolation considerations that determine product quality, and the tools available to researchers establishing MSC exosome programmes.
Early diagnosis of cancer is critical to treatment outcome. Cancer cells are revealing themselves, secreting vast numbers of extracellular vesicles into the blood. The race is on to identify these hallmarks of cancer with the target of simple mass testing to catch the disease early.
Tangential flow filtration (aka Cross flow filtrati is the method of choice when sample volume, yield and scalability are the primary requirements. It is the only isolation approach that can process litre-scale conditioned media volumes in a single continuous run without filter fouling, and it simultaneously concentrates EVs to a small, analytically ready output volume.
The isolation of extracellular vesicles (EVs) and exosomes is one of the most critical and variable steps in any EV research workflow. The most commonly used non-affinity isolation methods are ultracentrifugation (UC), size exclusion chromatography (SEC), and tangential flow filtration (TFF). The method you choose directly determines the purity, yield and integrity of your isolated vesicles, and has downstream consequences for every subsequent characterisation step, including nanoparticle tracking analysis (NTA), western blot and functional assays
For decades, researchers have been searching for a reliable, clinically translatable way around this formidable BBB obstacle. Researchers in China may now have found one.
Theories can become pervasive without any real evidence. EVs, once thought as trash containers, are not alone: Stress causes stomach ulcers. Consensus had non-coding DNA as junk. We look at past examples and current science that, perhaps, should not be counted as settled.
By analysing tumour-derived material circulating in blood, urine, or other body fluids, liquid biopsies offer a minimally invasive window into cancer biology in real time. Among the various analytes being explored, including circulating tumour cells (CTCs) and cell-free DNA (cfDNA), extracellular vesicles (EVs) are emerging as particularly compelling biomarker candidates.
